Cargando…
Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study
Autores principales: | Williams, Thomas, Mishra, Rhea, Bharkhada, Brina, Shields, Aoife, Dorsey, Rachel, Chataway, Jeremy, Brownlee, Wallace J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606541/ https://www.ncbi.nlm.nih.gov/pubmed/35273069 http://dx.doi.org/10.1136/jnnp-2021-328340 |
Ejemplares similares
-
Prescription opioid use in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2023) -
Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria
por: Brownlee, Wallace J, et al.
Publicado: (2015) -
Lymphomatosis cerebri: a treatable cause of rapidly progressive dementia
por: Samani, Amit, et al.
Publicado: (2015) -
Is the incidence of hip fracture increasing among older men in England?
por: Neuburger, Jenny, et al.
Publicado: (2016) -
COVID-19 vaccine given to children with comorbidities in England, December 2020–June 2021
por: Aiano, Felicity, et al.
Publicado: (2022)